Emergent BioSolutions (EBS) Non Operating Income (2011 - 2026)
Emergent BioSolutions (EBS) posted quarterly Non Operating Income of $2.9 million for Q1 2026, down 93.22% year-over-year from $42.8 million in Q1 2025, and up 112.72% quarter-over-quarter from -$22.8 million in Q4 2025.
Emergent BioSolutions (EBS) Non Operating Income (2011 - 2026) Analysis & Trends
Emergent BioSolutions' Non Operating Income history runs 16 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 93.22% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at -$57.2 million (down 257.58% YoY), while the FY2025 annual figure was -$17.3 million, up 49.42% from the prior year.
- Non Operating Income for Q1 2026 stood at $2.9 million, up from -$22.8 million in the prior quarter.
- The five-year high for Non Operating Income was $77.9 million in Q3 2024, with the low at -$66.3 million in Q2 2024.
- The 5-year median for Non Operating Income is -$13.0 million (2023), against an average of -$6.0 million.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income soared 495.37% in 2023, then slumped 255.27% in 2024.
- Emergent BioSolutions' Non Operating Income stood at -$6.1 million in 2022, then slumped by 75.41% to -$10.7 million in 2023, then plunged by 69.16% to -$18.1 million in 2024, then fell by 25.97% to -$22.8 million in 2025, then soared by 112.72% to $2.9 million in 2026.
- Business Quant data shows EBS's Non Operating Income at $2.9 million in Q1 2026, -$22.8 million in Q4 2025, and -$18.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -224.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 5.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 41.90 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 10.70 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Emergent BioSolutions | 261.35 Mn | 120.45 Mn | 137.20 Mn | -41.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -41.20 Mn |
| Mar 31, 2026 | 2.90 Mn |
| Dec 31, 2025 | -22.80 Mn |
| Sep 30, 2025 | -18.90 Mn |
| Jun 30, 2025 | -18.40 Mn |
| Mar 31, 2025 | 42.80 Mn |
| Dec 31, 2024 | -18.10 Mn |
| Sep 30, 2024 | 77.90 Mn |
| Jun 30, 2024 | -66.30 Mn |
| Mar 31, 2024 | -27.70 Mn |
| Dec 31, 2023 | -10.70 Mn |
| Sep 30, 2023 | -23.80 Mn |
| Jun 30, 2023 | 42.70 Mn |
| Mar 31, 2023 | -13.00 Mn |
| Dec 31, 2022 | -6.10 Mn |
| Sep 30, 2022 | -21.90 Mn |
| Jun 30, 2022 | -10.80 Mn |
| Mar 31, 2022 | -10.20 Mn |
| Dec 31, 2021 | -9.90 Mn |
| Sep 30, 2021 | -10.80 Mn |